Previous 10 | Next 10 |
BOTHELL, Wash. , Dec. 2, 2019 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today announced several executive appointmen...
We hold shares of BioLife Solutions ( BLFS ) in the SHU portfolio and are still sitting on considerable profits, but the shares have retreated quite a bit lately. We can sort of live with the market reaction to BioLife's third-quarter figures , which were indeed disappointing. The company...
Image source: The Motley Fool. Biolife Solutions Inc (NASDAQ: BLFS) Q3 2019 Earnings Call Nov 12, 2019 , 4:30 p.m. ET Operator Continue reading
BioLife Solutions, Inc. (BLFS) Q3 2019 Earnings Conference Call November 12, 2019, 04:30 PM ET Company Participants Roderick de Greef - CFO Mike Rice - President and CEO Conference Call Participants Paul Knight - Janney Faizzan Ahmad - H.C. Wainwright William March - Spri...
BioLife Solutions (NASDAQ: BLFS ): Q3 Non-GAAP EPS of $0.01 misses by $0.03 ; GAAP EPS of $0.37. More news on: BioLife Solutions, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
BOTHELL, Wash. , Nov. 12, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today announced the acquisition of substantially all of...
BOTHELL, Wash. , Nov. 12, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today reported financial results and operatio...
BOTHELL, Wash. , Nov. 7, 2019 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS) , a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today announced that based on revenue growth from 2015 to 2018, it has been selecte...
Fundamentally, Biolife Solutions Inc. ( BLFS ) is stronger than ever: year-to-year revenue growth of +29%, Gross Margins of 72%, successful recent acquisition of two tissue storage/transport companies that will add to the top and bottom lines, an ever-increasing list of customers, and posit...
BOTHELL, Wash. , Oct. 31, 2019 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS), a leading developer and supplier of best-in-class bioproduction tools for cell and gene therapies, ("BioLife" or the "Company"), today announced that the Company's third quarter 2019 financial re...
News, Short Squeeze, Breakout and More Instantly...
BioLife Solutions Inc. Company Name:
BLFS Stock Symbol:
NASDAQ Market:
BioLife Solutions Inc. Website:
BioLife Solutions to Report Second Quarter 2024 Financial Results and Business Update on August 8, 2024 PR Newswire BOTHELL, Wash. , July 25, 2024 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction...
BioLife Solutions Introduces the CellSeal CryoCase™ at International Society for Cell & Gene Therapies (ISCT) Conference in Vancouver BioLife Solutions Introduces the CellSeal CryoCase™ at International Society for Cell & Gene Therapies (ISCT) Conference in Vancouv...
BioLife Solutions Reports First Quarter 2024 Financial Results PR Newswire Cell Processing revenue increased 10% sequentially to $16.2 million GAAP gross margin of 38% and net loss of $10.2 million Non-GAAP adjusted gross margin expands ...